J-Pharma Presented the latest findings on LAT1 inhibitor NANVURANLAT (development code: JPH203) at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI2024)

January 22, 2024 J-Pharma Co., Ltd. For Print J-Pharma Co. Ltd. (Headquarters: Yokohama, Kanagawa Prefecture, President & CEO Masuhiro Yoshitake) announces the latest findings on its LAT1 inhibitor Nanvuranlat which were presented in a poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2024) held in San Francisco, California, USA. 1. Poster Session: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract 2. Date and Time: January 19, 2024, 12:30 – 14:00 (local time) 3. Abstract Number: 483 4. Abstract Title Treatment outcomes by stratifying the N-acetyl transferase 2 phenotype in pre-treated patients with advanced refractory biliary tract cancer treated an ad-hoc analysis of a randomized, double-blind, placebo-controlled phase 2 study. 5. First Presenter Dr. Naohiro Okano, M.D., Ph.D Assistant Professor, Department of Medical Oncology, School of Medicine, Kyorin University Faculty of Medicine [For further information, please contact.] J-Pharma Co., Ltd., Administration Department, Public Relations TEL: 045-506-1155 FAX: 045-506-1156 Mail: [email protected]

The release as fetched from its publisher. j-pharma.com ↗